IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
This study has been completed.
Sponsor:
Aptevo Therapeutics
Information provided by (Responsible Party):
Aptevo Therapeutics
ClinicalTrials.gov Identifier:
NCT00614042
First received: January 25, 2008
Last updated: June 26, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and non-Hodgkin's lymphoma.
| Condition | Intervention | Phase |
|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) Non-Hodgkin's Lymphoma (NHL) | Drug: TRU-016 (anti-CD37 protein therapeutic) | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | A Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Lymphosarcoma
Chronic Lymphocytic Leukemia
Leukemia, B-cell, Chronic
U.S. FDA Resources
Further study details as provided by Aptevo Therapeutics:
Primary Outcome Measures:
- Safety and tolerability of TRU-016 administered IV in patients with CLL or NHL [ Time Frame: 4 weeks after treatment ]
Secondary Outcome Measures:
- Preliminary indication of response as defined by NCI 1996 criteria [ Time Frame: 3 months after treatment ]
| Enrollment: | 96 |
| Study Start Date: | January 2008 |
| Study Completion Date: | March 2012 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Dose escalation and expansion cohorts
|
Drug: TRU-016 (anti-CD37 protein therapeutic)
TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
|
Detailed Description:
This Phase 1/1b open-label study consists of two parts. The initial portion is a Phase 1 dose-escalation study evaluating the safety and tolerability of TRU-016 administered over a 4-week period to patients with relapsed chronic lymphocytic leukemia (CLL). It will identify the MTD and evaluate the pharmacokinetics and immunogenicity of TRU-016. Upon demonstrating satisfactory safety and tolerability in the Phase 1 portion, a Phase 1b expansion cohort will be enrolled to further characterize the safety of the selected dose from the first stage of the study and safety and to estimate the clinical activity of TRU-016 in patients with treatment-naive CLL, relapsed CLL and non-Hodgkin's lymphoma.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of chronic lymphocytic lymphoma or small lymphocytic lymphoma (Phase 1) or relapsed/refractory NHL (Phase 1b)
- Previous treatment with at least one fludarabine-containing regimen
-
Demonstrate at least one of the following criteria for active disease requiring treatment:
- a)progressive splenomegaly and/or lymphadenopathy;
- b)anemia or thrombocytopenia due to bone marrow involvement;
- c)unintentional weight loss >10% over preceding 6-month period;
- d) NCI Grade 2 or 3 fatigue;
- e) fevers >100.5 F or night sweats for > 2 weeks without infection;
- f) progressive lymphocytosis with increase of >50% over a 2-month period or anticipated doubling time of < 6 months.
- ECOG performance status </= 2
- SGOT, SGPT </= 2.0 x upper limit of normal
- ANC >/= 500/uL
- Platelets >/= 30,000/uL
- Discontinued previous anticancer or investigational therapy for at least 30 days
Exclusion Criteria:
- Treatment with rituximab within 30 days or alemtuzumab(Campath)or radioimmune therapy within 12 weeks
- ANC </= 500/uL
- Platelets </= 30,000/mm3
- Previous or concurrent additional malignancy
- Significant concurrent medical diseases or conditions
- Hepatitis B surface antigen or hepatitis B core antibody positive
- Pregnant or breastfeeding
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00614042
Please refer to this study by its ClinicalTrials.gov identifier: NCT00614042
Locations
| United States, Alabama | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Birmingham, Alabama, United States, 35294 | |
| United States, Georgia | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Augusta, Georgia, United States, 30912 | |
| United States, Massachusetts | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Boston, Massachusetts, United States, 02111 | |
| United States, Nevada | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Las Vegas, Nevada, United States, 89135 | |
| United States, North Carolina | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Durham, North Carolina, United States, 27710 | |
| United States, Oregon | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Portland, Oregon, United States, 97239 | |
| United States, Washington | |
| For additional information regarding sites for this trial call 919-319-9374 | |
| Seattle, Washington, United States, 98109 | |
Sponsors and Collaborators
Aptevo Therapeutics
Investigators
| Study Director: | Scott Stromatt, MD | Aptevo Therapeutics |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Aptevo Therapeutics |
| ClinicalTrials.gov Identifier: | NCT00614042 History of Changes |
| Other Study ID Numbers: |
16007 |
| Study First Received: | January 25, 2008 |
| Last Updated: | June 26, 2017 |
Keywords provided by Aptevo Therapeutics:
|
CLL NHL TRU-016 chronic lymphocytic leukemia non-Hodgkin's lymphoma |
Additional relevant MeSH terms:
|
Lymphoma Leukemia Lymphoma, Non-Hodgkin Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Immunoglobulin G Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on August 18, 2017